This study will look into a new study medicine called NNC0519-0130 to improve the treatment option for people living with excess body weight or type 2 diabetes or both. The purpose of this study is to compare the amount of NNC0519-0130 in the blood of participants who have excess body weight. The study comprises two parts and the participants will receive both preparations NNC0519-0130 B and NNC0519-0130 C, which treatment the participants get is decided by chance. The study will last for about 24 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
46
NNC0519-0130 B will be administered subcutaneously.
NNC0519-0130 C will be administered subcutaneously.
ICON
San Antonio, Texas, United States
AUC,NNC0519-0130,SS: Area under the NNC0519-0130 plasma concentration-time curve during a dosing interval at steady state (SS)
Measured in hours\*nanomoles per liter (h\*nmol/L).
Time frame: From pre-dose up to 7 days post-dose
Cmax,NNC0519-0130,SS: Maximum plasma concentration of NNC0519-0130 at steady state
Measured in nanomoles per liter (nmol/L).
Time frame: From pre-dose up to 7 days post-dose
Number of adverse events
Measured in number of events.
Time frame: From time of first dosing (day 1) until completion of the end of study visit (day 141/162)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.